Lyon, France, November 6, 2019 – MaaT Pharma announced today that a poster will be presented at the American…
Categorie
2019
Jean-Marc Renard, MS, MBA, joins as Chief Business Officer Emmanuel Prestat, PhD, joins as Computational Biology Manager Lyon, France, September…
September 10, 2019
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute GvHD with no safety concerns…
August 13, 2019
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute GvHD with no safety concerns…
June 24, 2019
– First patents to cover the fundamental processes for accessing the human gut microbiome as biotherapeutics – – MaaT Pharma’s…
May 21, 2019
“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute (PRI), are working in collaboration…
May 21, 2019
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD Lyon, France, April 09,…
April 9, 2019
Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France, February 5, 2019 – MaaT Pharma announced…
February 5, 2019
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.